106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies: orders@GuidelineCentral.com
Copyright © 2014 All rights reserved
AAAIHAE14053
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be
considered exclusive of other methods of care reasonably directed at obtaining the same results. e
ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer
consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.
Abbreviations
ACE-I, angiotensin converting enzyme inhibitor; AE, angioedema; bid, twice a day; FDA, US
Food and Drug Administration; g, gram; HAE, hereditary angioedema; INH, inhibitor; IV,
intravenous; kg, kilogram; mg, milligrams; mL, milliliter; NL, normal; PO, by mouth; q3d,
every 3 days; q3-4d, every 3 to 4 days; tid, 3 times a day
Source
Joint Task Force on Practice Parameters ( JTFPP), representing the American Academy of
Allerg y, Asthma and Immunolog y; the American College of Allerg y, Asthma and Immunolog y;
and the Joint Council of Allerg y, Asthma and Immunolog y. A focused parameter update:
Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme
inhibitor–associated angioedema. J Allerg y Clin Immunol 2013;131:1491-3.
Grading System for Recommendations
Category/Grade Definition
Level of Evidence
Ia Evidence from meta-analysis of randomized controlled trials
Ib Evidence from at least one randomized controlled trial
IIa Evidence from at least one controlled study without randomization
IIb Evidence from at least one other type of quasi-experimental study
III Evidence from non-experimental descriptive studies, such as
comparative studies
IV Evidence from expert committee reports or opinions or clinical
experience of respected authorities or both
Strength of Recommendation
A Directly based on category I evidence
B Directly based on category II evidence or extrapolated
recommendation from category I evidence
C Directly based on category III evidence or extrapolated
recommendation from category I or II evidence
D Directly based on category IV evidence or extrapolated
recommendation from category I, II, or III evidence
LB (Lab Based)
